Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study

Teriflunomide is a once-daily oral immunomodulator approved for the treatment of relapsing–remitting multiple sclerosis. This post hoc analysis of the Phase III TOWER study evaluated the effects of teriflunomide treatment on five severe relapse outcomes: relapses with sequelae defined by an increase...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Aaron E., Macdonell, Richard, Comi, Giancarlo, Freedman, Mark S., Kappos, Ludwig, Mäurer, Mathias, Olsson, Tomas P., Wolinsky, Jerry S., Bozzi, Sylvie, Dive-Pouletty, Catherine, O’Connor, Paul W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155167/
https://www.ncbi.nlm.nih.gov/pubmed/24972678
http://dx.doi.org/10.1007/s00415-014-7395-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155167/
https://www.ncbi.nlm.nih.gov/pubmed/24972678
http://dx.doi.org/10.1007/s00415-014-7395-7

Ejemplares similares